宁波市劳动监察规定
宁波市人民政府
宁波市劳动监察规定
宁波市人民政府
第一条 为了保证劳动法律、法规、规章的贯彻实施,维护劳动关系双方的合法权益,根据《中华人民共和国劳动法》和其他有关法律、法规,结合本市实际,制定本规定。
第二条 对本市行政区域内企业、事业单位,雇工的个体工商户(以下统称用人单位)以及与之发生劳动关系的劳动者的劳动监察,适用本规定。
第三条 本规定所称劳动监察,是指劳动行政部门设立专门机构对用人单位和劳动者遵守劳动法律、法规、规章情况进行监督检查,对违反劳动法律、法规、规章的行为进行教育、制止,责令改正,并予以处罚的劳动行政执法行为。
对用人单位和劳动者遵守劳动安全、矿山安全和锅炉及压力容器安全情况的监督检查,按照有关法律、法规、规章的规定执行。
第四条 劳动监察坚持以事实为根据,以法律为准绳的原则和坚持劳动行政部门专门监察与群众监督相结合,教育与处罚相结合的原则。
第五条 各企业、事业单位主管部门、公安、工商、财税、人民银行等有关部门,应在各自职责范围内,协同劳动行政部门做好劳动监察工作。
各级工会依法维护劳动者的合法权益,对用人单位遵守劳动法律、法规、规章的情况进行监督。
任何组织和个人对违反劳动法律、法规、规章的行为有权向劳动监察机构检举和控告。
第六条 市、县(市、区)劳动行政部门设立劳动监察机构。
市劳动监察机构负责对市属单位和部属、省属、部队属以及外地驻宁波市区单位的劳动监察。
县(市、区)劳动监察机构负责对本行政区域内所管辖单位的劳动监察。
法律、法规、规章对劳动监察管辖另有规定的,按照其规定执行。
第七条 劳动监察机构配备专职和兼职劳动监察员。专职劳动监察员是劳动行政部门专门从事劳动监察工作的人员;兼职劳动监察员是劳动行政部门中非专门从事劳动监察工作的人员。
劳动监察员应从熟悉劳动业务、掌握劳动法律知识、坚持原则、秉公办事、能胜任劳动监察工作的人员中选任。
第八条 劳动监察机构行使下列职责:
(一)宣传劳动法律、法规、规章和政策,督促用人单位和劳动者正确贯彻执行;
(二)对用人单位和劳动者进行监督检查,依法纠正和查处违反劳动法律、法规、规章的行为;
(三)对劳动监察人员进行培训和监督;
(四)法律、法规、规章规定的其他劳动监察职责。
第九条 劳动监察的内容为:
(一)社会劳务中介机构和社会培训机构遵守有关规定的情况;
(二)劳动合同的订立和履行情况;
(三)用人单位招聘职工的行为;
(四)劳动者的工作时间;
(五)企业遵守企业工资总额宏观调控规定的情况;
(六)用人单位支付职工工资情况;
(七)国有企业经营者的收入情况;
(八)用人单位和劳动者缴纳社会保险费情况;
(九)社会保险费给付情况;
(十)用人单位遵守职工福利规定的情况;
(十一)用人单位和劳动者遵守职业技能开发规定的情况;
(十二)社会职业技能考核鉴定机构对劳动者职业技能考核鉴定及发放证书的情况;
(十三)承办境外承包工程、对外劳务合作、公民个人出境就业的机构维护境外就业人员合法权益的情况;
(十四)法律、法规、规章规定的其他事项。
第十条 劳动监察采取常规监察、随时抽查和违法案件专项查处等方式。
对因用人单位违反劳动法律、法规、规章而引发的突发事件,劳动监察机构应当及时介入,配合有关部门进行教育、疏导、做好处理工作。
第十一条 劳动监察人员在履行劳动监察职责时,应有两名以上劳动监察员共同进行,并出示《中华人民共和国劳动监察证》。
劳动监察人员根据工作需要可以随时进入用人单位了解和检查贯彻实施劳动法律、法规、规章的情况,调阅有关资料,向有关人员查询。必要时,可向用人单位或劳动者下达《劳动监察询问通知书》、《劳动监察限期整改指令书》(以下简称《询问书》、《指令书》),并要求其在收
到《询问书》或《指令书》之日起十日内据实向劳动监察机构作出书面答复。
劳动监察人员在履行职责时,不得向他人泄露案情及用人单位的有关保密资料,并应当为举报人保密和为被检查单位保守商业秘密。
第十二条 各级劳动监察机构应当设立举报信箱,公布举报电话。
任何单位和个人均可以对劳动违法行为进行举报。
第十三条 向劳动监察机构举报,应当有明确的被举报者的名称、地址及其违法事实。
第十四条 查处违反劳动法律、法规、规章的行为,依照下列程序进行:
(一)登记立案。对发现的违法行为,经过审查,认为有违法事实,需要依法追究的,应当登记立案。
(二)调查取证。对已立案的案件,应当在立案之日起十五日内组织调查取证。
(三)处理。在调查取证后,对需要追究法律责任的案件,劳动行政部门应当在立案之日起两个月内作出处理决定。处理决定作出前,劳动行政部门应当听取当事人申辩。
(四)制作处罚决定书。劳动行政部门作出处罚决定,应当制作处罚决定书。
(五)送达。劳动行政部门在处罚决定作出之日起七日内,应当将处罚决定书送达当事人。处罚决定书自送达当事人之日起生效。
第十五条 劳动监察员对事实清楚、证据确凿、情节简单的劳动违法行为,可以当场处理。当场处理应当填写当场处理决定书,并递交当事人。
当事人对当场处理有异议的,应当按照本规定第十四条办理。
第十六条 对用人单位违反劳动法律、法规、规章的行为,依照有关法律、法规、规章的规定执行。有下列行为之一的,由劳动行政部门责令其限期改正,并可根据情节予以处罚:
(一)由于用人单位的原因,不与劳动者签订劳动合同或合同期满继续使用不续订劳动合同的,由劳动监察机构予以教育,并责令补签劳动合同;拒不改正的,按未签订劳动合同人数每人每月处以50元的罚款;
(二)用人单位违反规定克扣职工工资的,责令补发工资,赔偿职工的经济损失,并可处以克扣工资额五倍以下的罚款;
(三)用人单位无故不缴纳或故意漏缴、少缴社会保险费的,责令其限期缴纳;逾期不缴的,按日加收应缴额2‰的滞纳金;
(四)对超出业务范围从事非法劳务中介活动,未经批准擅自开办职业介绍机构的,责令其改正,没收非法所得,吊销职业介绍许可证,并可处以5000元以下的罚款。
(五)职业培训、鉴定机构违反有关培训考核、鉴定规定,伪造、滥发各种证书的,没收其非法所得并可处5000元以下的罚款。
第十七条 用人单位有下列行为之一的,由劳动监察机构予以批评教育,责令改正,拒不改正的,处以10000元以下的罚款;对法定代表人或直接责任人处以1000元以下罚款;构成犯罪的,由劳动行政部门提请司法机关对责任人员依法追究刑事责任:
(一)隐瞒事实真相,出具伪证,或者隐匿、毁灭证据的;
(二)拒绝提供有关资料的;
(三)拒绝在规定的时间和地点就劳动监察机构所提问题作出解释和说明的;
(四)劳动监察机构发出《指令书》后未按规定整改的;
(五)无理阻挠劳动监察机构工作人员依法行使监察职权的;
(六)打击报复举报人和劳动监察人员的。
第十八条 用人单位有下列行为之一的,处以5000元以下的罚款;对责任人员由公安机关按照《治安管理处罚条例》予以处罚;构成犯罪的,由司法机关依法追究刑事责任:
(一)以暴力、威胁或者非法限制人身自由的手段强迫劳动的;
(二)侮辱、体罚、殴打、非法搜查和拘禁劳动者的。
第十九条 对劳动者违反劳动法律、法规、规章行为的处罚,按照有关法律、法规、规章的规定执行。
第二十条 劳动行政部门应当加强对劳动监察人员的教育、管理和监督。对越权或非公务场合使用劳动监察证件,或利用职权谋取私利违法乱纪的劳动监察人员,应当予以批评教育;情节严重的,由任命机关撤销任命,收缴其劳动监察证件,并给予行政处分;触犯刑律的,由司法机关
依法追究刑事责任。
第二十一条 罚款使用财政部门统一印制的罚款票据;罚款全额上缴同级财政。
第二十二条 用人单位或者劳动者对劳动行政处罚决定不服的,可依法申请复议或提起诉讼。复议和诉讼期间,不影响原决定的执行。
逾期不申请复议、不起诉又不履行处罚决定的,劳动行政部门可依法申请人民法院强制执行。
第二十三条 本规定由市劳动局负责解释。
第二十四条 本规定自发布之日起施行。
1995年11月18日
Provisions for Supervision of Drug Distribution
Commissioner of SFDA
Provisions for Supervision of Drug Distribution
(SFDA Decree No.26)
The Provisions for Supervision of Drug Distribution, adopted at the executive meeting of the State Food and Drug Administration on December 8, 2006, is hereby promulgated and shall go into effect as of May 1, 2007.
Shao Mingli
Commissioner of SFDA
January 31, 2007
Provisions for Supervision of Drug Distribution
Chapter I
Article 1 These Provisions are formulated for the purposes of strengthening drug supervision, regulating drug distribution order and ensuring drug quality in accordance with the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Regulations for Implementation of the Drug Administration Law) and the requirements of the relevant law and regulations.
Article 2 Any institutions or individuals engaged in the purchase, sales and supervision of drugs in the People’s Republic of China shall abide by the Provisions.
Article 3 Drug manufacturers, distributors and medical institutions shall be responsible for the quality of the drugs that they produce, distribute or use.
Drug manufacturers and distributors shall carry out reforms and innovations in the direction of pharmaceutical logistics provided that drug quality is assured.
Article 4 The drug regulatory departments encourage individuals and organizations to involve in the social supervision on drug distribution. Individuals or organizations have the right to report or accuse of any violation of the Provisions to the drug regulatory departments.
Chapter II Supervision on Drug Purchase and Sales by Manufacturers and Distributors
Article 5 Drug manufacturers or distributors shall be responsible for their drug purchases and sales, and liable for the purchases and sales activities of their sales staff or offices in the name of their enterprise.
Article 6 Drug manufacturers or distributors shall train their purchase and sales staff on drug related laws, regulations and professional knowledge, and establish training records including time, venue, content and trainees.
Article 7 Drug manufacturers or distributors shall strengthen the management of the sales staff and set up specific rules for their sales behaviors.
Article 8 Drug manufacturers or distributors shall not store or spot trade drugs on the premises not approved by the drug regulatory departments.
Article 9 Drug manufacturers shall sell drugs that they produce in the name of themselves, and shall not sell any drug that they produce for contract manufacturing or any drugs produced by others.
Article 10 Where a drug manufacturer or wholesaler sells drugs, it shall provide the following materials:
(1) Copies of the Drug Manufacturing Certificate or Drug Supply Certificate, stamped with the seal of the enterprise, and the business license;
(2) Copies of the approval documents for the drug to be sold, stamped with the seal of the enterprise ;
(3) For import drug sales, relevant proof documents should be provided in accordance with the related provisions of the State.
Where a drug manufacturer or wholesaler sends any of its sales staff to sell drugs, it shall, in addition to the materials prescribed in the previous paragraph of this Article, provide a copy of the authorization letter with the seal of the enterprise. The original authorization letter shall contain the authorized drugs, regions and time of validity for drug sales, indicate the identity card numbers of the sales staff, and be stamped with the enterprise seal and legal representative seal (or signature). The sales staff shall show the original authorization letter and identity card for the check by drug purchasers.
Article 11 Where a drug manufacturer or wholesaler sells drugs, it shall provide sales document indicating supplier’s name, drug name, manufacturer, batch number, quantity, price, etc.
Where a drug retailer sells drugs, it shall provide sales document indicating drug name, manufacturer, quantity, price, batch number, etc.
Article 12 Where a drug manufacturer or distributor purchases drugs, it shall request, examine and retain the relevant certificates and documents of the supplier in accordance with the requirements set forth in Article 10 of the Provisions, and request and retain sales document in accordance with the requirements set forth in Article 11 of the Provisions.
The documents retained by the drug manufacturer or distributor in accordance with the previous paragraph of this Article shall be kept till one year after the date of expiry, but not less than three years.
Article 13 Where a drug manufacturer or distributor knows or should know that any person without certificates produces or distributes drugs, it shall not provide the person with any drug.
Article 14 A drug manufacturer or distributor shall not provide premises, qualifications documents, notes, etc. as conveniences for others to distribute drugs in its own name.
Article 15 A drug manufacturer or distributor shall not spot trade drugs by means of exhibition, exposition, trade fair, commodity fair or product promotion event.
Article 16 A drug distributor shall not purchase or sell pharmaceutical preparations prepared by medical institutions.
Article 17 A drug distributor shall not change its distribution mode without approval of the drug regulatory department.
A drug distributor shall operate within the approved distribution scope in the Drug Supply Certificate.
Article 18 A drug retailer shall, pursuant to the requirements of drug classification regulations set forth by the State Food and Drug Administration, sell prescription drugs in the presence of prescriptions.
Any drug retailer selling prescription drugs or Class A non-prescription drugs shall, in the absence of its licensed pharmacists and other qualified pharmaceutical professionals, put up a public notice and stop selling prescription drugs and Class A non-prescription drugs.
Article 19 For drugs that need low-temperature or cold storage as specified in drug insert sheets, the drug manufacturer or distributor shall transport and store the drugs with low-temperature or cold storage facilities in accordance with the relevant provisions.
When finding any drug manufacturer or distributor violates the requirements in the previous paragraph of this article, the drug regulatory department shall seal up or seize the drugs concerned immediately and deal with the matter in accordance with law.
Article 20 A drug manufacturer or distributor shall not provide the public with prescription drug or Class A non-prescription drug by means of tie-in sale, offering free drugs in association with sales of drug or commodity sale, etc.
Article 21 A drug manufacturer or distributor shall not sell prescription drugs directly to the public by post or over internet.
Article 22 Any illegal purchase of drugs is prohibited.
Chapter III Supervision on Drug Purchase and Storage by Medical Institutions
Article 23 The pharmacy established by a medical institution shall have the premise, equipment, storage facilities, hygienic environment, and pharmaceutical professionals required for drug dispensing. It shall also have the drug quality control units or personnel, and establish a system for drug storage.
Article 24 Where a medical insititution purchases drugs, it shall request, examine and retain the relevant certificates, documents and notes of the supplier in accordance with the requirements set forth in Article 12 of the Provisions.
Article 25 Where a medical institution purchases drugs, it shall establish and apply an examination and acceptance system, and keep authentic and complete purchase records. Purchase records shall indicate the adopted name of the drug in China, manufacturer (for Chinese crude drug, the origin should be noted), dosage form, date of expiry, drug approval number, supplier, quantity, price and date of purchase.
Drug purchase records shall be kept till one year after the date of expiry, but not less than three years.
Article 26 A medical institution shall establish and apply a system for drug storage and maintenance, and take necessary measures to ensure drug quality, such as cold storage, protection against freeze and humidity, ventilation, moisture proof, protection from direct light and fire, and avoidance of insects and rodents.
A medical institution shall store drugs and non-drug products separately; Chinese crude drugs, prepared slices of Chinese crude drugs, pharmaceuticals, and traditional Chinese medicine preparations shall be stored separately by category.
Article 27 A medical institution or family planning technical service institution shall not directly provide drugs for patients without diagnosis or treatment.
Article 28 A medical institution shall not sell prescription drugs directly to the public by post or over internet.
Article 29 Where a medical institution purchases drugs via a centralized tendering, it shall comply with the relevant requirements of the Drug Administration Law, Regulations for Implementation of the Drug Administration Law and the Provisions.
Chapter IV Legal Liabilities
Article 30 In any of the following circumstances, the drug manufacturer or distributor shall be instructed to rectify within a time limit and given a disciplinary warning; and if the drug manufacturer or distributor fails to do so, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan:
(1) any drug manufacturer or distributor in violation of Article 6 of the Provisions;
(2) any drug manufacturer or wholesaler in violation of the first paragraph of Article 11 of the Provisions;
(3) any drug manufacturer or distributor, in violation of Article 12 of the Provisions, failing to keep the relevant documents as required.
Article 31 Any drug manufacturer or distributor in violation of Article 7 of the Provisions shall be given a disciplinary warning and instructed to rectify within a time limit.
Article 32 In accordance with the provisions in Article 73 of the Drug Administration Law, in any of the following circumstances, the drugs illegally sold and the illegal gains therefrom shall be confiscated, and the drug manufacturer or distributor shall be fined not less than two times but not more than five times the value of the drugs illegally sold:
(1) any drug manufacturer or distributor, in violation of Article 8 of the Provisions, spot trading drugs on the premises not approved by the drug regulatory departments.
(2) any drug manufacturer in violation of Article 9 of the Provisions;
(3) any drug manufacturer or distributor in violation of Article 15 of the Provisions;
(4) any drug distributor in violation of Article 17 of the Provisions.
Article 33 Any drug manufacturer or distributor, in violation of Article 8 of the Provisions, storing drugs on the premises not approved by the drug regulatory departments,shall be punished pursuant to the provisions in Article 74 of the Regulations for Implementation of the Drug Administration Law.
Article 34 Any drug retailer in violation of the provisions in the second paragraph of Article 11 of the Provisions shall be instructed to rectify and given a disciplinary warning; and if the drug retailer fails to do so within a time limit, it shall be fined not more than RMB 500 yuan.
Article 35 Where a drug manufacturer or distributor, in violation of Article 13 of the Provisions, knows or should know that any person without certificates produces or distributes drugs, but still provide the person with drugs, they shall be given a disciplinary warning, instructed to rectify and fined not more than RMB 10,000 yuan. If the circumstances are serious, they shall be fined not less than RMB 10,000 yuan but not more than RMB 30,000 yuan.
Article 36 Drug manufacturers and distributors in violation of Article 14 of the Provisions shall be punished pursuant to the provisions in Article 82 of the Drug Administration Law.
Article 37 Where a drug distributor, in violation of Article 16 of the Provisions, purchases or sells pharmaceutical preparations dispensed by medical institutions, it shall be punished pursuant to the provisions in Article 80 of the Drug Administration Law.
Article 38 Any drug retailer in violation of the first paragraph of Article 18 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so or the circumstances are serious, it shall be fined not more than RMB 1,000 yuan.
Where a drug retailer, in violation of the second paragraph of Article 18 of the Provisions, sells prescription drugs or Class A non-prescription drugs in absence of licensed pharmacists or other qualified pharmaceutical professionals, it shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so, it shall be fined not more than RMB 1,000 yuan.
Article 39 Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to transport drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be given a disciplinary warning and instructed to rectify within a time limit; if it fails to do as instructed, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.
Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to store drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be punished pursuant to the provisions in Article 79 of the Drug Administration Law. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.
Article 40 Any drug manufacturer or distributor in violation of Article 20 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if the drug manufacturer or distributor fails to do so or the circumstances are serious, they shall be fined not more than two times the value of the free drugs offered, but not more than RMB 30,000 yuan.
Article 41 Any institution, in violation of Article 23 to Article 27 of the Provisions, shall be instructed to rectify within a time limit; if the circumstances are serious, it shall be announced.
Article 42 Where a drug manufacturer or distributor in violation of Article 21 of the Provisions or a medical institution in violation of Article 28 of the Provisions sells prescription drugs directly to the public by post, over internet, etc., they shall be instructed to rectify, given a disciplinary warning, and fined not more than two times the value of the drugs sold, but not more than RMB 30,000 yuan.
Article 43 Any illegal purchase of drugs, in violation of Article 22 of the Provisions, shall be punished pursuant to the provisions in Article 73 of the Drug Administration Law.
Article 44 Where a drug regulatory department or its staff that neglects its duty fails to stop or punish illegal activities that should be stopped or punished, administrative sanctions shall be imposed to the person directly in charge and other persons directly responsible. If a crime is constituted, criminal liabilities shall be investigated in accordance with law.
Chapter V Supplementary Provisions
Article 45 Spot trading of drugs in the Provisions refers to the activity that drug manufacturers, distributors or their appointed sales staff carry and sell drugs to unspecified objects on spot other than the premises approved by the drug regulatory departments.
Article 46 With respect to the supervision on the distribution of specially controlled drugs, vaccines, and military medicines, if otherwise provided by the relevant laws, regulations and provisions, they shall prevail.
Article 47 The Provisions shall come into force as of May 1, 2007. As of the date when the Provisions goes into effect, the Provisions for Supervision of Drug Distribution (Interim) (SFDA Decree No.7) implemented on August 1, 1999 shall be annulled therefrom.